Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Oct 2019: Trial registered, NCT04118764

The trials

NCT04118764: Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound

State
Completed
Phase
No phase
People
6 taking part
Started
6 Aug 2020
Primary completion
11 Jul 2022
Arms
Focused ultrasound treatment
Results
Posted on the registry
  1. 8 Oct 2019: Trial registered
  2. 6 Aug 2020: Trial started
  3. 28 Sep 2022: Trial completed
  4. 26 Aug 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.